Back to Search
RAYMOND ROTHER, PH.D., LCSW-C
PH.D., LCSW-C
Clinical Social Worker
NPI: 1538203773IndividualAccepts Medicare
Specialties, Licenses & Credentials
Clinical Social WorkerPrimary
Social Worker — Clinical
Code: 1041C0700X
09526(MD)
CMS Specialties
PrimaryCLINICAL SOCIAL WORKER
Education
OTHER
Class of 1993
Research & Publications (20)
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.
PMID 19372265·Blood·2009
5-case
Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex.
PMID 19131645·Circ Res·2009
7-preclinical
Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.
PMID 19399743·Liver Transpl·2009
5-case
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
PMID 18503589·Br J Haematol·2008
3-trial
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
PMID 18055865·Blood·2008
3-trial
C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients.
PMID 18444931·Am J Transplant·2008
7-preclinical
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
PMID 18184663·Brain·2008
7-preclinical
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis.
PMID 18056404·J Immunol·2007
7-preclinical
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
PMID 17989688·Nat Biotechnol·2007
7-preclinical
Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation.
PMID 17878341·J Immunol·2007
7-preclinical
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
PMID 17702897·Blood·2007
3-trial
The effects of the fibrin-derived peptide Bbeta(15-42) in acute and chronic rodent models of myocardial ischemia-reperfusion.
PMID 17505302·Shock·2007
7-preclinical
Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
PMID 17405753·Haematologica·2007
5-case
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
PMID 16990386·N Engl J Med·2006
3-trial
Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
PMID 16464755·Haematologica·2005
5-case
C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm.
PMID 16078298·Br J Surg·2005
7-preclinical
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
PMID 15985537·Blood·2005
3-trial
Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury.
PMID 15972690·J Immunol·2005
7-preclinical
Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine.
PMID 15880054·Transplantation·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 340 PARK AVE
FREDERICK, MD 21701 - Phone
- (301) 663-1683
Quick Facts
- NPI
- 1538203773
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile